Larger companies often limit their strategic pharmacovigilance activities outsourcing only to highly manual and repetitive tasks, while the smaller ones may want to outsource their entire pharmacovigilance system. But is there anything in between?
- How can larger companies benefit from outsourcing strategic pharmacovigilance activities while maintaining full control and compliance?
- How can small/medium-sized companies get access to a serious pharmacovigilance database that grows with them without having to break the bank?
- What are the advantages of scalable and tailor-made outsourcing models?
- How can the pharmaceutical companies obtain benefits from the scalability and standardization required to ensure central oversight while also retaining local effectiveness?
You will learn about strategic pharmacovigilance activities outsourcing through scalable and tailor-made outsourcing models and how it can be done in a controlled way:
1. Full pharmacovigilance outsourcing
- What does it mean?
- How will you remain in control?
2. Outsourcing a pharmacovigilance database
- How to select a proper database?
- How to get access to it without buying it yourself?
- What control levels can you opt for?
3. Outsourcing specific strategic pharmacovigilance activities
- How to remain in control?
Optimizing your pharmacovigilance activities?
Make use of our experts’ invaluable know-how in managing pharmacovigilance activities while remaining in control.
Who should attend?
- Global QPPVs / Deputies
- QPPV Office managers
- Heads of Pharmacovigilance
- Heads of Pharmacovigilance Technologies
- Drug Safety Managers
- Drug Safety Leaders involved in Risk Management, Aggregate Safety reports, Oversight and Standards
Duration: 50 min.
Speakers:
- Head of Global Pharmacovigilance, Martijn van de Leur;
- International QPPV, Olga Asimaki;
- QPO Manager and Head of Pharmacovigilance Technologies, Gediminas Zvicevičius.
Martijn van de Leur, MSc
Head of Global Pharmacovigilance
Other content that might interest you:
Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries
Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of experience and adequate know-how. This webinar focuses on choosing your...
CMC: Effective Writing Of IND And IMPD
This artical focuses on best practices in delivering an effective CMC writing strategy when writing an IND or IMPD.
Webinar: Effective IMPD Writing. The Quality Part
Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is required by competent authorities in EU. The...
